ID   MZ1851RC
AC   CVCL_E045
SY   MZ1851-RCC; MZ 1851 RC; MZ-1851-RC; MZ1851
DR   Wikidata; Q54907243
RX   CelloPub=CLPUB00420;
RX   PubMed=7989126;
RX   PubMed=8864171;
RX   PubMed=8900424;
RX   PubMed=9816317;
RX   PubMed=10074909;
RX   PubMed=17200335;
RX   PubMed=23696916;
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_X418 ! MZ1851LN
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 10
//
RX   CelloPub=CLPUB00420;
RA   Bukur J.H.;
RT   "Characterization of T cell responses against human renal cell
RT   carcinoma and identification of HLA-G as a tumor-associated antigen
RT   and immune evasion mechanism of renal cell carcinoma.";
RL   Thesis PhD (2004); Johannes Gutenberg University Mainz; Mainz; Germany.
//
RX   PubMed=7989126; DOI=10.1002/ijc.2910590621;
RA   Bernhard H., Karbach J., Wolfel T., Busch P., Storkel S., Stockle M.,
RA   Wolfel C., Seliger B., Huber C., Meyer zum Buschenfelde K.-H.,
RA   Knuth A.;
RT   "Cellular immune response to human renal-cell carcinomas: definition
RT   of a common antigen recognized by HLA-A2-restricted cytotoxic
RT   T-lymphocyte (CTL) clones.";
RL   Int. J. Cancer 59:837-842(1994).
//
RX   PubMed=8864171; DOI=10.1111/j.1399-0039.1996.tb02601.x;
RA   Bernhard H., Jager E., Maeurer M.J., Meyer zum Buschenfelde K.-H.,
RA   Knuth A.;
RT   "Tumor associated antigens in human renal cell carcinoma: MHC
RT   restricted recognition by cytotoxic T lymphocytes.";
RL   Tissue Antigens 48:22-31(1996).
//
RX   PubMed=8900424; DOI=10.1002/(SICI)1097-0215(19961009)68:2<177::AID-IJC6>3.0.CO;2-V;
RA   Brouwenstijn N., Gaugler B., Kruse K.M., van der Spek C.W., Mulder A.,
RA   Osanto S., van den Eynde B.J., Schrier P.I.;
RT   "Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones
RT   isolated from peripheral blood lymphocytes and tumor-infiltrating
RT   lymphocytes.";
RL   Int. J. Cancer 68:177-182(1996).
//
RX   PubMed=9816317;
RA   Seliger B., Hohne A., Knuth A., Bernhard H., Ehring B., Tampe R.,
RA   Huber C.;
RT   "Reduced membrane major histocompatibility complex class I density and
RT   stability in a subset of human renal cell carcinomas with low TAP and
RT   LMP expression.";
RL   Clin. Cancer Res. 2:1427-1433(1996).
//
RX   PubMed=10074909; DOI=10.1002/(SICI)1097-0215(19990315)80:6<799::AID-IJC1>3.0.CO;2-U;
RA   Dumas F., Gala J.-L., Berteau P., Brasseur F., Eschwege P., Paradis V.,
RA   Lacour B., Philippe M., Loric S.;
RT   "Molecular expression of PSMA mRNA and protein in primary renal
RT   tumors.";
RL   Int. J. Cancer 80:799-803(1999).
//
RX   PubMed=17200335; DOI=10.1158/1078-0432.CCR-06-0824;
RA   Seliger B., Fedorushchenko A., Brenner W., Ackermann A., Atkins D.,
RA   Hanash S.M., Lichtenfels R.;
RT   "Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell
RT   carcinoma associated with enhanced tumor cell proliferation and
RT   migration.";
RL   Clin. Cancer Res. 13:27-37(2007).
//
RX   PubMed=23696916; PMCID=PMC3657351;
RA   Stoehr C.G., Buettner-Herold M., Kamphausen E., Bertz S., Hartmann A.,
RA   Seliger B.;
RT   "Comparative expression profiling for human endoplasmic
RT   reticulum-resident aminopeptidases 1 and 2 in normal kidney versus
RT   distinct renal cell carcinoma subtypes.";
RL   Int. J. Clin. Exp. Pathol. 6:998-1008(2013).
//